http://orcid.org/0000-0001-7723-9501
Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Hue Tu Quach, Zhaohua Hou, Rebecca Y. Bellis, Jasmeen K. Saini, Alfredo Amador-Molina, Prasad S. Adusumilli & Yuquan Xiong. (2022) Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1. Expert Opinion on Investigational Drugs 31:11, pages 1187-1202.
Read now
Read now
Yi-Quan Jiang, Zi-Xian Wang, Ming Zhong, Lu-Jun Shen, Xue Han, Xuxiazi Zou, Xin-Yi Liu, Yi-Nan Deng, Yang Yang, Gui-Hua Chen, Wuguo Deng & Jin-Hua Huang. (2021) Investigating Mechanisms of Response or Resistance to Immune Checkpoint Inhibitors by Analyzing Cell-Cell Communications in Tumors Before and After Programmed Cell Death-1 (PD-1) Targeted Therapy: An Integrative Analysis Using Single-cell RNA and Bulk-RNA Sequencing Data. OncoImmunology 10:1.
Read now
Read now
Rita Greco, Hongjing Qu, Hui Qu, Joachim Theilhaber, Gary Shapiro, Richard Gregory, Christopher Winter, Natalia Malkova, Frank Sun, Julie Jaworski, Annie Best, Lily Pao, Andrew Hebert, Mikhail Levit, Alexei Protopopov, Jack Pollard, Keith Bahjat, Dmitri Wiederschain & Sharad Sharma. (2020) Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. OncoImmunology 9:1.
Read now
Read now
Xianguang Bai, Ming Yi, Ying Jiao, Qian Chu & Kongming Wu. (2019) Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. OncoTargets and Therapy 12, pages 9527-9538.
Read now
Read now
Jiajing Cai, Dongsheng Wang, Guoyuan Zhang & Xiaolan Guo. (2019) The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy. OncoTargets and Therapy 12, pages 8437-8445.
Read now
Read now
Anja C. Bloom, Lewis H. Bender, Shweta Tiwary, Lise Pasquet, Katharine Clark, Tianbo Jiang, Zheng Xia, Aizea Morales-Kastresana, Jennifer C. Jones, Ian Walters, Masaki Terabe & Jay A. Berzofsky. (2019) Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. OncoImmunology 8:10.
Read now
Read now
Hendrik Ungefroren. (2019) Blockade of TGF-β signaling: a potential target for cancer immunotherapy?. Expert Opinion on Therapeutic Targets 23:8, pages 679-693.
Read now
Read now
Jessica J. O'Konek, Elena Ambrosino, Anja C. Bloom, Lise Pasquet, Chandirasegaran Massilamany, Zheng Xia, Masaki Terabe & Jay A. Berzofsky. (2018) Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. OncoImmunology 7:7.
Read now
Read now
Karin M. Knudson, Kristin C. Hicks, Xiaoling Luo, Jin-Qiu Chen, Jeffrey Schlom & Sofia R. Gameiro. (2018) M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. OncoImmunology 7:5.
Read now
Read now
Reginald M Gorczynski & Fang Zhu. (2017) Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. Cancer Management and Research 9, pages 601-609.
Read now
Read now
Articles from other publishers (53)
Zachary Gao, Sung Wook Kang, Derek Erstad, Joseph Azar, George Van Buren, William Fisher, Zequn Sun, Mark P. Rubinstein, Hyun-Sung Lee & E. Ramsay Camp. (2023) Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer. Frontiers in Oncology 13.
Crossref
Crossref
Sumeet Singh, Vinita Gouri & Mukesh Samant. (2023) TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer. Medical Oncology 40:11.
Crossref
Crossref
Riajul Wahab, Md Mahedi Hasan, Zulfikar Azam, Paul J. Grippo & Taslim A. Al-Hilal. (2023) The role of coagulome in the tumor immune microenvironment. Advanced Drug Delivery Reviews 200, pages 115027.
Crossref
Crossref
Mengke Niu, Ming Yi, Yuze Wu, Lijuan Lyu, Qing He, Rui Yang, Liang Zeng, Jian Shi, Jing Zhang, Pengfei Zhou, Tingting Zhang, Qi Mei, Qian Chu & Kongming Wu. (2023) Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Tianye Li, Xinrun Wang, Mengke Niu, Mingli Wang, Jianwei Zhou, Kongming Wu & Ming Yi. (2023) Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Crossref
Yihao Wu, Yizhou Xu & Linhao Xu. (2023) Drug therapy for myocarditis induced by immune checkpoint inhibitors. Frontiers in Pharmacology 14.
Crossref
Crossref
Yunpeng Yao, Jianhua Li, Kuo Qu, Yangeng Wang, Zhe Wang, Wenting Lu, Yongli Yu & Liying Wang. (2022) Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor. Cancer Immunology, Immunotherapy 72:5, pages 1103-1120.
Crossref
Crossref
Christianne Groeneveldt, Jurriaan Q. van Ginkel, Priscilla Kinderman, Marjolein Sluijter, Lisa Griffioen, Camilla Labrie, Diana J.M. van den Wollenberg, Rob C. Hoeben, Sjoerd H. van der Burg, Peter ten Dijke, Lukas J.A.C. Hawinkels, Thorbald van Hall & Nadine van Montfoort. (2023) Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy. Cancer Research Communications 3:2, pages 325-337.
Crossref
Crossref
Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Zhenyu Zhao & Kongming Wu. (2022) TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy. Frontiers in Immunology 13.
Crossref
Crossref
Anastasia E. Metropulos, Hidayatullah G. Munshi & Daniel R. Principe. (2022) The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial. eBioMedicine 86, pages 104380.
Crossref
Crossref
Max Kam-Kwan Chan, Jeff Yat-Fai Chung, Philip Chiu-Tsun Tang, Alex Siu-Wing Chan, Johnny Yuk-Yeung Ho, Tony Pak-Tik Lin, Jiaoyi Chen, Kam-Tong Leung, Ka-Fai To, Hui-Yao Lan & Patrick Ming-Kuen Tang. (2022) TGF-β signaling networks in the tumor microenvironment. Cancer Letters 550, pages 215925.
Crossref
Crossref
Briana G. Nixon, Shengyu Gao, Xinxin Wang & Ming O. Li. (2022) TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective. Nature Reviews Immunology.
Crossref
Crossref
Hong Kyu Lee, Cho-Won Kim, Dohee Ahn, Ryeo-Eun Go, Youngdong Choi & Kyung-Chul Choi. (2022) Next-Generation Antisense Oligonucleotide of TGF-β2 Enhances T Cell-Mediated Anticancer Efficacy of Anti-PD-1 Therapy in a Humanized Mouse Model of Immune-Excluded Melanoma. Cancers 14:21, pages 5220.
Crossref
Crossref
Bangling Han, Tianyi Fang, Yao Zhang, Yongle Zhang, Jialiang Gao & Yingwei Xue. (2022) Association of the TGFβ gene family with microenvironmental features of gastric cancer and prediction of response to immunotherapy. Frontiers in Oncology 12.
Crossref
Crossref
Seyed Amir Sanatkar, Arash Heidari & Nima Rezaei. (2022) Cancer Immunotherapy: Diverse Approaches and Obstacles. Current Pharmaceutical Design 28:29, pages 2387-2403.
Crossref
Crossref
Ayuob Aghanejad, Samad Farashi Bonab, Maryam Sepehri, Fatemeh Sadat Haghighi, Ali Tarighatnia, Christopher Kreiter, Nader D. Nader & Mohammad Reza Tohidkia. (2022) A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors. International Journal of Biological Macromolecules 207, pages 592-610.
Crossref
Crossref
Naomi Kaisar-Iluz, Ludovica Arpinati, Merav E. Shaul, Sojod Mahroum, Mohamad Qaisi, Einat Tidhar & Zvi G. Fridlender. (2022) The Bilateral Interplay between Cancer Immunotherapies and Neutrophils’ Phenotypes and Sub-Populations. Cells 11:5, pages 783.
Crossref
Crossref
Daniele V. F. Tauriello, Elena Sancho & Eduard Batlle. (2021) Overcoming TGFβ-mediated immune evasion in cancer. Nature Reviews Cancer 22:1, pages 25-44.
Crossref
Crossref
Ying Ni, Ahmed Soliman, Amy Joehlin-Price, Peter G. Rose, Anda Vlad, Robert P. Edwards & Haider Mahdi. (2021) High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. npj Precision Oncology 5:1.
Crossref
Crossref
Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou & Kongming Wu. (2021) The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Anupreet Kharbanda, Phuc Tran, Lingtian Zhang, Yuet-Kin Leung, Hong-yu Li & Brendan Frett. (2021) Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology. European Journal of Medicinal Chemistry 225, pages 113763.
Crossref
Crossref
Aditi Gupta, Sadna Budhu, Kelly Fitzgerald, Rachel Giese, Adam O. Michel, Aliya Holland, Luis Felipe Campesato, Jacques van Snick, Catherine Uyttenhove, Gerd Ritter, Jedd D. Wolchok & Taha Merghoub. (2021) Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Communications Biology 4:1.
Crossref
Crossref
Anupreet Kharbanda, Lingtian Zhang, Debasmita Saha, Phuc Tran, Ke Xu, Ming O. Li, Yuet-Kin Leung, Brendan Frett & Hong-yu Li. (2021) Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors. European Journal of Medicinal Chemistry 223, pages 113660.
Crossref
Crossref
Joseph T. Decker, Jeffrey A. Ma, Lonnie D. Shea & Jacqueline S. Jeruss. (2021) Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer. Cancers 13:21, pages 5343.
Crossref
Crossref
Christina H. Stuelten & Ying E. Zhang. (2021) Transforming Growth Factor-β: An Agent of Change in the Tumor Microenvironment. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Adela Wu & Michael Lim. (2021) The Challenges and Future of Immunotherapy for Gliomas. The Cancer Journal 27:5, pages 371-378.
Crossref
Crossref
Wanqiang ShengYi LiuDamayanti ChakrabortyBrian DeboYang Shi. (2021) Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti–PD-1 Treatment. Cancer Discovery 11:8, pages 1970-1981.
Crossref
Crossref
Min Wang, Xiaoyang Zhai, Ji Li, Jingyuan Guan, Shuhui Xu, YuYing Li & Hui Zhu. (2021) The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Frontiers in Immunology 12.
Crossref
Crossref
Espen Basmo Ellingsen, Sara M. Mangsbo, Eivind Hovig & Gustav Gaudernack. (2021) Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. Frontiers in Immunology 12.
Crossref
Crossref
Pavlina Chuntova, Frances Chow, Payal B Watchmaker, Mildred Galvez, Amy B Heimberger, Evan W Newell, Aaron Diaz, Ronald A DePinho, Ming O Li, E John Wherry, Duane Mitchell, Masaki Terabe, Derek A Wainwright, Jay A Berzofsky, Christel Herold-Mende, James R Heath, Michael Lim, Kim A Margolin, E Antonio Chiocca, Noriyuki Kasahara, Benjamin M Ellingson, Christine E Brown, Yvonne Chen, Peter E Fecci, David A Reardon, Gavin P Dunn, Linda M Liau, Joseph F Costello, Wolfgang Wick, Timothy Cloughesy, William C Timmer, Patrick Y Wen, Robert M Prins, Michael Platten & Hideho Okada. (2021) Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology 23:3, pages 356-375.
Crossref
Crossref
Stefania Canè, Jacques Van Snick, Catherine Uyttenhove, Luc Pilotte & Benoit J Van den Eynde. (2021) TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism. Journal for ImmunoTherapy of Cancer 9:2, pages e001798.
Crossref
Crossref
Vivian Weiwen Xue, Jeff Yat-Fai Chung, Cristina Alexandra García Córdoba, Alvin Ho-Kwan Cheung, Wei Kang, Eric W.-F. Lam, Kam-Tong Leung, Ka-Fai To, Hui-Yao Lan & Patrick Ming-Kuen Tang. (2020) Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity. Cancers 12:11, pages 3099.
Crossref
Crossref
Ning Kang, Mark Eccleston, Pier-Luc Clermont, Maryam Latarani, David Kingsley Male, Yuzhuo Wang & Francesco Crea. (2020) EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics 12:16, pages 1457-1476.
Crossref
Crossref
Anca Dorhoi, Leigh A. Kotzé, Jay A. Berzofsky, Yongjun Sui, Dmitry I. Gabrilovich, Ankita Garg, Richard Hafner, Shabaana A. Khader, Ulrich E. Schaible, Stefan H.E. Kaufmann, Gerhard Walzl, Manfred B. Lutz, Robert N. Mahon, Suzanne Ostrand-Rosenberg, William Bishai & Nelita du Plessis. (2020) Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. Journal of Clinical Investigation 130:6, pages 2789-2799.
Crossref
Crossref
Christianne Groeneveldt, Thorbald van Hall, Sjoerd H. van der Burg, Peter ten Dijke & Nadine van Montfoort. (2020) Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses. Trends in Immunology 41:5, pages 406-420.
Crossref
Crossref
Anne-Ulrike Trendelenburg. 2020. Anti-fibrotic Drug Discovery. Anti-fibrotic Drug Discovery
1
36
.
Alessandra Metelli, Bill X. WuBrian RiesenbergSilvia Guglietta, John D. HuckCatherine Mills, Anqi LiSaleh Rachidi, Carsten Krieg, Mark P. Rubinstein, Daniel T. GewirthShaoli SunMichael B. LillyAmy H. WahlquistDavid P. Carbone, Yiping YangBei Liu & Zihai Li. (2020) Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-β. Science Translational Medicine 12:525.
Crossref
Crossref
Bozena Kaminska & Salwador Cyranowski. 2020. Glioma Signaling. Glioma Signaling
179
201
.
E. Dodagatta-Marri, D. S. Meyer, M. Q. Reeves, R. Paniagua, M. D. To, M. Binnewies, M. L. Broz, H. Mori, D. Wu, M. Adoumie, R. Del Rosario, O. Li, T. Buchmann, B. Liang, J. Malato, F. Arce Vargus, D. Sheppard, B. C. Hann, A. Mirza, S. A. Quezada, M. D. Rosenblum, M. F. Krummel, A. Balmain & R. J. Akhurst. (2019) α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Merav E. Shaul & Zvi G. Fridlender. (2019) Tumour-associated neutrophils in patients with cancer. Nature Reviews Clinical Oncology 16:10, pages 601-620.
Crossref
Crossref
Didier Dréau, Laura Jeffords Moore, Mike Wu, Lopa Das Roy, Lloye Dillion, Travis Porter, Rahul Puri, Noor Momin, K. Dane Wittrup & Pinku Mukherjee. (2019) Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology 9.
Crossref
Crossref
Heng Sow, Jiang Ren, Marcel Camps, Ferry Ossendorp & Peter ten Dijke. (2019) Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. Cells 8:4, pages 320.
Crossref
Crossref
Hoyoung M. Maeng & Jay A. Berzofsky. (2019) Strategies for developing and optimizing cancer vaccines. F1000Research 8, pages 654.
Crossref
Crossref
Jay A. Berzofsky, Masaki Terabe, Jane B. Trepel, Ira Pastan, David F. Stroncek, John C. Morris & Lauren V. Wood. (2017) Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunology, Immunotherapy 67:12, pages 1863-1869.
Crossref
Crossref
Jente van Staalduinen, David Baker, Peter ten Dijke & Hans van Dam. (2018) Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?. Oncogene 37:48, pages 6195-6211.
Crossref
Crossref
Konstantin Knoblich, Sara Cruz Migoni, Susan M. Siew, Elizabeth Jinks, Baksho Kaul, Hannah C. Jeffery, Alfie T. Baker, Muath Suliman, Katerina Vrzalikova, Hisham Mehenna, Paul G. Murray, Francesca Barone, Ye H. Oo, Philip N. Newsome, Gideon Hirschfield, Deirdre Kelly, Steven P. Lee, Biju Parekkadan, Shannon J. Turley & Anne L. Fletcher. (2018) The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation. PLOS Biology 16:9, pages e2005046.
Crossref
Crossref
Masaki Terabe & Jay A. Berzofsky. (2018) Tissue-Specific Roles of NKT Cells in Tumor Immunity. Frontiers in Immunology 9.
Crossref
Crossref
Amina Dahmani & Jean-Sébastien Delisle. (2018) TGF-β in T Cell Biology: Implications for Cancer Immunotherapy. Cancers 10:6, pages 194.
Crossref
Crossref
Haruo Ohtani, Toru Terashima & Eiichi Sato. (2018) Immune cell expression of TGFβ1 in cancer with lymphoid stroma: dendritic cell and regulatory T cell contact. Virchows Archiv 472:6, pages 1021-1028.
Crossref
Crossref
Fang Zhu, Ismat Khatri, David Spaner & Reginald M. Gorczynski. (2018) An autologous tumor vaccine for CLL. Leukemia Research 68, pages 40-47.
Crossref
Crossref
Hoyoung Maeng, Masaki Terabe & Jay A Berzofsky. (2018) Cancer vaccines: translation from mice to human clinical trials. Current Opinion in Immunology 51, pages 111-122.
Crossref
Crossref
Ronald Anderson & Bernardo L. Rapoport. (2018) Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. Frontiers in Oncology 8.
Crossref
Crossref
Shingo Kato, Jay A. Berzofsky & Masaki Terabe. (2018) Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor Immunity. Frontiers in Immunology 9.
Crossref
Crossref